Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States

Journal of Dermatological Treatment

Volumn 21, Issue 5, 2010, Pages 276-281

  Alikhan, Ali ^a   Daly, Meaghan ^b   Wu, Jun ^c   Balkrishnan, Rajesh ^c   Feldman, Steven R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Fluocinolone; Hydroquinone; Melasma; Tretinoin; Tri Luma

Indexed keywords

FLUOCINOLONE ACETONIDE; HYDROQUINONE; RETINOIC ACID;

ARTICLE; CHLOASMA; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNITED STATES;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; DRUG COSTS; DRUG THERAPY, COMBINATION; FLUOCINOLONE ACETONIDE; HUMANS; HYDROQUINONES; MELANOSIS; OINTMENTS; TREATMENT OUTCOME; TRETINOIN; UNITED STATES;

EID: 77955452800     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903200612     Document Type: Article

References (26)

1. Vazquez M, Maldonado H, Benmaman C, Sanchez JL. Melasma in men. A clinical and histologic study. Int J Dermatol. 1988;27:25-27.
2. Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
3. Taylor SC. Epidemiology of skin diseases in people of color. Cutis 2003;71:271-275.
4. Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, Mihm MCJr. Melasma: A clinical, light microscopic, ultra- structural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698-710.
5. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, et al. Melasma: Histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146:228-237.
6. Balkrishnan R, McMichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol. 2003;149:572-577.
7. Balkrishnan R, Kelly AP, McMichael A, Torok H. Improved quality of life with effective treatment of facial melasma: The pigment trial. J Drugs Dermatol. 2004;3:377-381.
8. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048-1065.
9. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15: 894-899.
10. Vazquez M, Sanchez JL. The efficacy of a broad-spectrum sunscreen in the treatment of melasma. Cutis 1983;32:9295-9296.
11. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
12. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003;72:67-72.
13. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: A safe and efficacious 12-month treatment for melasma. Cutis 2005;75: 57-62.
14. Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol. 2005;4:592-597.
15. Grimes P, Kelly AP, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis 2006;77:177-184.
16. Cestari T, Adjadj L, Hux M, Shimizu MR, Rives VP. Cost- effectiveness of a fixed combination of hydroquinone/tretinoin/ fluocinolone cream compared with hydroquinone alone in the treatment of melasma. J Drugs Dermatol. 2007;6:153-160.
17. Ferreira Cestari T, Hassun K, Sittart A, de Lourdes Viegas M. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermatol. 2007;6:36-39.
18. Thomson Corporation. Red book. Montvale, NJ: Thomson PDR; 2008. p. v.
19. Lynfield YL, Schechter S. Choosing and using a vehicle. J Am Acad Dermatol. 1984;10:56-59.
20. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol. 1998;138:293-296.
21. Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exp Dermatol. 1991;16:444-447.
22. Grimes PE. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation. Cutis 2004;74:362-368.
23. Yoshimura K, Sato K, Aiba-Kojima E, Matsumoto D, Machino C, Nagase T, et al. Repeated treatment protocols for melasma and acquired dermal melanocytosis. Dermatol Surg. 2006;32:365-371.
24. Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Cutis 2008;81:365-371.
25. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrish- nan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-216.
26. Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydro- quinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697-703.